These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

By Shashwat Chauhan and Nikhil Sharma (Reuters) -European shares edged lower on Friday as elevated government bond yields ...

President-elect Donald Trump’s threat to slap Denmark with tariffs to force its hand in giving up Greenland could lead to ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...

Fundsmith Equity saw its fourth calendar year of underperforming the MSCI World Index and the third consecutive calendar year ...